CM
CYTK icon

Caption Management’s Cytokinetics CYTK Stock Holding History

Caption Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$81.1M Buy
1,230,000
+743,700
+153% +$47.3M 0.47% 35
2025
Q4 		$30.9M Buy
486,300
+191,200
+65% +$11.9M 0.21% 106
2025
Q3 		$16.2M Buy
295,100
+222,400
+306% +$9.16M 0.13% 174
2025
Q2 		$2.4M Buy
72,700
+62,200
+592% +$2.16M 0.03% 668
2025
Q1 		$422K Sell
10,500
-538,400
-98% -$24.7M ﹤0.01% 1143
2024
Q4 		$25.8M Buy
548,900
+415,200
+311% +$21.6M 0.24% 57
2024
Q3 		$7.06M Buy
133,700
+50,000
+60% +$2.79M 0.11% 217
2024
Q2 		$4.53M Sell
83,700
-392,200
-82% -$23.7M 0.07% 278
2024
Q1 		$33.4M Sell
475,900
-876,000
-65% -$67.8M 0.51% 37
2023
Q4 		$113M Buy
1,351,900
+1,348,600
+40,867% +$48.8M 1.52% 4
2023
Q3 		$97.2K Buy
+3,300
New +$110K ﹤0.01% 1154
2022
Q4 		– Sell
-60,000
Closed -$2.91M – 1358
2022
Q3 		$2.91M Hold
60,000
– – 0.04% 511
2022
Q2 		$2.36M Buy
60,000
+30,000
+100% +$1.21M 0.03% 617
2022
Q1 		$1.1M Hold
30,000
– – 0.01% 936
2021
Q4 		$1.37M Sell
30,000
-85,000
-74% -$3.28M 0.02% 924
2021
Q3 		$4.11M Buy
115,000
+69,000
+150% +$2.03M 0.05% 529
2021
Q2 		$911K Buy
+46,000
New +$1.08M 0.01% 926
2021
Q1 		– Sell
-32,500
Closed -$675K – 1111
2020
Q4 		$675K Sell
32,500
-409,000
-93% -$7.47M 0.02% 682
2020
Q3 		$9.56M Buy
441,500
+437,800
+11,832% +$10.2M 0.22% 99
2020
Q2 		$88K Buy
+3,700
New +$69.4K ﹤0.01% 837

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Caption Management's CYTK Position: Q1 2026 in Review

Caption Management increased its Cytokinetics (CYTK) stake by 775% in Q1 2026, buying an estimated $13.8M and bringing the position to 245,000 shares worth $16.1M. The position accounts for 0.09% of the portfolio, ranked #232.

Caption Management first reported a position in CYTK in Q2 2019 and has held it in 16 quarters since. The position peaked at $35.1M in Q4 2023. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Caption Management held 245,000 shares of Cytokinetics worth $16.1M as of Q1 2026.
  • Caption Management bought 217,001 Cytokinetics shares in Q1 2026, an estimated $13.8M.
  • Cytokinetics made up 0.09% of Caption Management's portfolio in Q1 2026, its #232 holding.
  • Caption Management first reported a position in Cytokinetics in Q2 2019 and has held it in 16 quarters since.
  • Caption Management's Cytokinetics position peaked at $35.1M in Q4 2023.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.